期刊文献+

241例青年乳腺癌临床分析 被引量:5

Clinical analysis of 241 younger women with breast cancer
下载PDF
导出
摘要 本文主要通过对甘肃省五家医院241例临床资料进行回顾性统计分析,按病理分型分析以浸润性导管癌174例(72.20%)为主。按TNM分期,Ⅱ、Ⅲ期病例占83.82%。5年生存率为57.96%、17.78%。其中12例Ⅳ期患者5年生存率为0,提示青年乳腺癌多数为浸润型癌,发展快、预后差。本研究旨在探讨青年乳腺癌的临床病理特征及与预后的关系,并期待能为甘肃省青年女性提供如何早期诊断及预防的措施,为更深入的研究提供临床依据。 This paper is majored in Gansu province through 241 clinical data of 5 hospitals which are retrospectively ana-lyzed according to the statistics,the analysis to the pathological type infiltrating ductal carcinoma 174 cases(72.20%).Ac-cording to TNM stage,Ⅱ,Ⅲ stage of 83.82%.The 5-year survival rate for 57.96%,17.78%.And 12 examples Ⅳ patient 5-year survival rate is 0,prompt the youth breast cancer most for the infiltration cancer,develops quickly,the prognosis is bad.This research aims to explore the clinical and pathological features of youth breast cancer and prognosis in Gansu province,and look forward to provide young women to early diagnosis and prevention measures for the further research and provide clinical evidence.
出处 《中国医药导报》 CAS 2010年第32期159-160,共2页 China Medical Herald
基金 甘肃省科技攻关计划项目[项目名称:甘肃省青年女性乳腺癌(35岁以下)发病的危险因素及对策研究 编号:2GS054-A43-014-07]
关键词 乳腺癌 青年女性 生存率 预后 Breast cancer Younger women Survival rate Prognosis
  • 相关文献

参考文献7

二级参考文献57

共引文献274

同被引文献43

  • 1马树东,罗荣城,丁彦青,刘来煜,蔡俊杰.乳腺癌组织中EGFR、IGF-1R、HER2/neu和p53蛋白的表达及意义[J].肿瘤防治杂志,2005,12(5):335-338. 被引量:12
  • 2李沛雨,陈凛,李荣,徐文通,蒋彦永.早期乳腺癌保乳治疗的局部复发因素分析[J].军医进修学院学报,2007,28(1):17-19. 被引量:1
  • 3赵荫农,何妮,欧超,曹骥,陈军,刘剑勇,袁卫平.乳腺肿瘤组织中EGFR与EGFRv Ⅲ的表达及临床意义[J].中华肿瘤防治杂志,2007,14(3):185-188. 被引量:5
  • 4何英,唐利立.国人早期乳腺癌远处转移预报模型的研究[J].中国普通外科杂志,2007,16(4):360-362. 被引量:3
  • 5Bock GH,Putter H,Bonnema J, et al. The impact of locore- gional recurrences on metastatic progression in early-stage breast cancer:A muhistate model [J].Breast Cancer Res Treat,2009 117(2) :401-408.
  • 6Botteri E,Bagnardi V,Rotmensz N,et al. Analysis of local and regional recurrences in breast cancer after conservative surgery [J]. Ann Oncol,2010,21 (4) :723-728.
  • 7Bouganim N,Tsvetkova E,Clemons M,et al. Evolution of sites of recurrence after early breast cancer over the last 20 years : implications for patient care and future research [J]. Breast Cancer Res Treat, 2013,139 C 2 ) : 603-606.
  • 8Lower EE,Glass E,Blau R,et al. HER-2/neu expression in primary and metastatic breast cancer [J]. Breast Cancer Res Treat, 2009,113 (2) : 301-306.
  • 9Santinelli A,Pisa E,Stramazzotti D,et al. HER-2 status discrepancy between primary breast cancer and metastaticsites.Impact on target therapy [J]. International Journal of Cancer,2008,122(5) :999-1004.
  • 10Von MG,du Bois A,Sehrnidt M,et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2, positive advanced breast eancer:A German Breast Group 26/ Breast International Group 03-05 study [J]. Journal of Clinical Ontology, 2009,27 (12) : 1999-2006.

引证文献5

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部